Zepbound, the brand version of tirzepatide, remains a viable weight loss treatment for individuals grappling with multiple obesity-related conditions such as hypertension and high cholesterol.
In a study conducted by Eli Lilly, researchers explored the efficacy of the drug in facilitating weight loss among individuals with obesity who also contend with additional medical ailments. The study, which is set to be presented at the Endocrine Society’s annual meeting in Boston, analyzed data from 4,726 participants across four distinct trials. Notably, all subjects exhibited obesity or overweight status alongside other health conditions linked to obesity, with nearly 20% of them diagnosed with type 2 diabetes. The findings revealed that individuals administered Zepbound experienced more significant weight loss compared to those given a placebo, irrespective of the presence of other medical conditions.
Zepbound belongs to a group of medications known as GLP-1 drugs, or glucagon-like peptide1 receptor agonists, which also includes Ozempic, Wegovy, and Saxenda. By mimicking or enhancing the effects of a naturally occurring gut hormone responsible for regulating blood sugar levels, these drugs can reduce appetite by targeting hunger centers in the brain. Approved by the Food and Drug Administration (FDA) in November 2023 for weight loss in adults grappling with obesity or overweight status coupled with at least one related condition like type 2 diabetes, high cholesterol, or high blood pressure, Zepbound offers a promising solution for weight management.
However, it’s essential to understand that while all GLP-1 drugs exhibit efficacy across various medical conditions, Zepbound stands out due to its unique attributes. According to Mir Ali, MD, a bariatric surgeon and medical director at MemorialCare Surgical Weight Loss Center, Zepbound’s effectiveness is attributed to its multifaceted impact on different receptors. Unlike other GLP-1 drugs, Zepbound influences not only the GLP-1 receptor but also the GIP receptor, both crucial in regulating hunger, satiety, and motility.
Dan Azagury, MD, FACS, the chief bariatric surgeon and medical director of Stanford University School of Medicine’s Lifestyle and Weight Management Clinic, corroborates the study’s findings, emphasizing the broad effectiveness of GLP-1 drugs. While potential side effects vary among individuals and aren’t necessarily contingent on their medical conditions, both Azagury and Ali stress the importance of using these medications as intended, coupled with proper support from healthcare providers.
In essence, while Zepbound and similar medications offer valuable tools for weight management, achieving sustainable results requires a holistic approach encompassing dietary modifications, lifestyle changes, and ongoing support from healthcare professionals.
